In spite of all the medical progress, hypertension remains a highly prevalent chronic disease
worldwide, contributing importantly to cardiovascular morbidity and mortality in Europe 1 …

After three years of excessive confidence, overoptimistic expectations and performance of
15 to 20,000 renal denervation procedures in Europe, the failure of a single well-designed …

Seven years after the first patient was treated with the Symplicity Arch catheter by Murray
Esler and colleagues in Melbourne, Australia, 1 our knowledge about the renal sympathetic …

The 6-year anniversary of the first catheter-based renal denervation procedure for resistant
hypertension has passed, and the 3-year follow-up results of the Symplicity HTN-1 are now …

Because there was no control group in Symplicity HTN-1, a subsequent trial (Symplicity HTN-
2) was initiated as a multicenter, randomized, controlled trial. 15 The inclusion criteria were …

Following the publication of the randomized controlled but open-label trial Symplicity HTN-2,
catheter-based renal sympathetic denervation was proposed as a novel treatment for drug …

We read with interest the recent meta-analysis by Davis et al.(1) on the blood pressure (BP)–
lowering effects of renal denervation (RDN) in treatment-resistant hypertensive patients. The …

Ever since Schlaich et al. 1 first reported on a patient with a blood pressure of 161/107 mm
Hg (despite treatment with seven different antihypertensive drugs) that decreased to 127/81 …

Resistant hypertension is a common medical problem that is increasing with the advent of
an increasingly older and heavier population. The etiology of resistant hypertension is …

We read with interest the paper by Bhatt et al 1 published in the New England Journal of
Medicine. In summary, the blinded SYMPLICITY HTN-3 trial did not show a significant …